- Home
- SOL vs PLRX Comparison
SOL vs PLRX Comparison
Compare SOL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- PLRX
- Stock Information
- Founded
- SOL 2005
- PLRX 2015
- Country
- SOL United States
- PLRX United States
- Employees
- SOL N/A
- PLRX N/A
- Industry
- SOL Semiconductors
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- PLRX Health Care
- Exchange
- SOL Nasdaq
- PLRX Nasdaq
- Market Cap
- SOL 98.5M
- PLRX 89.0M
- IPO Year
- SOL 2008
- PLRX 2020
- Fundamental
- Price
- SOL $1.88
- PLRX $1.45
- Analyst Decision
- SOL Strong Buy
- PLRX Hold
- Analyst Count
- SOL 2
- PLRX 10
- Target Price
- SOL $4.50
- PLRX $3.93
- AVG Volume (30 Days)
- SOL 155.6K
- PLRX 1.0M
- Earning Date
- SOL 08-19-2025
- PLRX 08-07-2025
- Dividend Yield
- SOL N/A
- PLRX N/A
- EPS Growth
- SOL N/A
- PLRX N/A
- EPS
- SOL N/A
- PLRX N/A
- Revenue
- SOL $68,445,000.00
- PLRX N/A
- Revenue This Year
- SOL N/A
- PLRX N/A
- Revenue Next Year
- SOL $45.37
- PLRX N/A
- P/E Ratio
- SOL N/A
- PLRX N/A
- Revenue Growth
- SOL N/A
- PLRX N/A
- 52 Week Low
- SOL $1.04
- PLRX $1.10
- 52 Week High
- SOL $3.00
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- SOL 50.12
- PLRX 43.13
- Support Level
- SOL $1.82
- PLRX $1.40
- Resistance Level
- SOL $1.90
- PLRX $1.65
- Average True Range (ATR)
- SOL 0.03
- PLRX 0.11
- MACD
- SOL -0.00
- PLRX -0.03
- Stochastic Oscillator
- SOL 51.29
- PLRX 15.49
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.